US Senate Committee Backs Bill to Restrict Chinese Biotechnology Firms’ Access to American Genetic Data
The U.S. Senate’s homeland security committee has voted 11-1 in favor of the Prohibiting Foreign...
HKG: 2359
WuXi ATU’s Philadelphia Facility Approved for Amtagvi Production Following FDA Nod
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec (SHA: 603259, HKG:...
US Senate Puts Brakes on Bill Targeting China-Based CDMOs Amid Stock Market Reactions
A US Congress bill aimed at prohibiting US-funded entities from engaging with various China-based contract...
WuXi AppTec Expands Peptide Manufacturing Capacity with Two New Plants in China
WuXi AppTec (HKG: 2359, SHA: 603259), a leading China-based Contract Research, Development, and Manufacturing Organization...
CORXEL Partners with WuXi STA for Sterile Nasal Spray Production
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, backed by RTW Investments, has formed a...
Shanghai Updates Biomedical R&D Import Pilot for Streamlined Customs Clearance
The Shanghai Municipal Commission of Commerce, in collaboration with Shanghai Customs and the Shanghai Municipal...
WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023
China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for...
SanReno Therapeutics Partners with WuXi STA for Comprehensive R&D and Manufacturing Services
Shanghai-based kidney drug developer SanReno Therapeutics has entered into a partnership with WuXi STA, a...
Stemirna Therapeutics Halts mRNA Vaccine Factory Construction Amid Low Demand
China-based Stemirna Therapeutics Co., Ltd has decided to halt the construction of a factory intended...
WuXi AppTec Reports 5.77% YOY Revenue Growth and 31.97% Increase in Net Profits for 2023Q1
WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for the...
WuXi Advanced Therapies (WuXi ATU) Closes Manufacturing Facilities in Shanghai Due to Market Changes
Media reports indicate that WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused Contract...
WuXi AppTec Reports 71.8% Revenue Growth in 2022 Financials
China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) released its 2022 financial report, recording...
WuXi AppTec Posts Stellar Q3 2022 Results with 209% Profit Surge
China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its Q3 2022 financial...
Biden’s Executive Order Boosts US Bio-Economy, Targets China’s Biotech Rise
US President Joe Biden signed an executive order on Monday, outlining steps to bolster the...
WuXi ATU Partners with Wugen to Accelerate NK Cell Therapy Development
WuXi ATU, the gene and cell therapy-focused CTDMO unit of WuXi Apptec (SHA: 603259, HKG:...
WuXi AppTec Faces Shareholder Divestment of Up to 3% Stake
China-based Contract Research Organization (CRO) WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has disclosed...